Nanomedicine review: clinical developments in liposomal applications

Cancer Nanotechnology

Table 12 Toxicity of the clinical trials to amphotericin B

References	Disease	LF	Toxicity Grade 3–5 (%)
References	Disease	LF	Hk	Ld	C	Na	D	AP	V	P	H
Cornely et al. (2017)	IFD	AmBisome^®								28	8
Rahman et al. (2017)	VL	AmBisome^® + Mil			2	3	2	2	18	18
		AmBisome^® + Par			0	0	0	1	1	22
		AmBisome^®								23
Miyao et al. (2016)	RFN	AmBisome^®	11.25	2.5
Wasunna et al. (2016)^a	VL	AmBisome^® + SSG			4^b				2
Wasunna et al. (2016)^a	VL	AmBisome^® + Mil			6^b				12

In the blanks, this type of toxicity is not reported
IFD invasive fungal diseases, VL visceral leishmaniasis, RFN refractory febrile neutropenia, Ld liver dysfunction, Hk hypokalemia, C cardiotoxicity, Na nauseas, D diarrhea, AP abdominal pain, V vomiting, P pneumonia, H hypotension, Mil, miltefosine, Par paromycin, SSG sodium stibogluconate, LF liposomal formulation
^aNo grade > 3 toxicity was reported
^bSinus arrhythmia

ISSN: 1868-6966